Cargando…

Spotlight on Topical Long-Term Management of Plaque Psoriasis

During the 28th Congress of the European Academy of Dermatology and Venereology (EADV) held in Madrid in October 2019, an industry hub was dedicated to the long-term management of psoriasis. Psoriasis is a systemic inflammatory disease primarily involving the skin that affects up to 4% of the Europe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carrascosa, Jose Manuel, Theng, Colin, Thaçi, Diamant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397561/ https://www.ncbi.nlm.nih.gov/pubmed/32801825 http://dx.doi.org/10.2147/CCID.S254114

Ejemplares similares

Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy
por: Imafuku, Shinichi, et al.
Publicado: (2018)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies
por: Griss, Johannes, et al.
Publicado: (2023)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases
por: Mössner, Rotraut, et al.
Publicado: (2008)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
por: MELIN, Audrey, et al.
Publicado: (2021)

General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach
por: Thaçi, Diamant, et al.
Publicado: (2020)

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
por: Krueger, James, et al.
Publicado: (2022)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
por: Giunta, Alessandro, et al.
Publicado: (2017)

Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation
por: Sarafian, Golnaz, et al.
Publicado: (2015)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients
por: Boch, Katharina, et al.
Publicado: (2022)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series
por: Ständer, Sascha, et al.
Publicado: (2020)

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
por: Tsianakas, Athanasios, et al.
Publicado: (2022)

Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis
por: Iraji, Fariba, et al.
Publicado: (2014)

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care
por: da Silva, Neuza, et al.
Publicado: (2020)

Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis
por: Frantz, Travis, et al.
Publicado: (2019)

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
por: Gerdes, S., et al.
Publicado: (2017)

Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
por: Menter, Alan, et al.
Publicado: (2017)

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
por: Gordon, Kenneth B., et al.
Publicado: (2022)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
por: Kowalzick, Lutz
Publicado: (2009)

Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy
por: Segaert, Siegfried, et al.
Publicado: (2017)

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
por: Nicolescu, Alin Codrut, et al.
Publicado: (2022)

The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer
por: Esteban-Jurado, Clara, et al.
Publicado: (2016)

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
por: von Stebut, Esther, et al.
Publicado: (2020)

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)
por: Gordon, K.B., et al.
Publicado: (2020)

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study
por: Thaçi, D., et al.
Publicado: (2019)

Bacterial colonization of psoriasis plaques. Is it relevant?
por: Marcus, Eva, et al.
Publicado: (2011)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
por: Wasel, Norman, et al.
Publicado: (2020)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla, Leelavathy, et al.
Publicado: (2019)

Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports
por: Apalla, Zoe, et al.
Publicado: (2022)

Guselkumab for plaque psoriasis
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c7or1djkdve8ot0tsj8r3dk18j